Literature DB >> 24136566

A review of treatment of uterine leiomyosarcomas.

Nicholas Reed1.   

Abstract

Uterine leiomyosarcomas are rare but challenging tumours. They occur most commonly around or shortly after the menopause. Their clinical behaviour is very variable, from highly aggressive to very indolent. Most are diagnosed unexpectedly and thus initially operated on by general gynaecologists. This article discusses the important surgical issues and the role of adjuvant treatments such as radiotherapy and chemotherapy. Important new international trials are opening to address these issues. Relapsed disease is usually incurable, but a subgroup of patients may benefit from repeated surgical procedures, hormones and ablative therapies. The choice of drugs for chemotherapy is discussed. New approaches with targeted agents have yet to establish themselves in treatment of leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24136566     DOI: 10.1007/s11912-013-0350-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  82 in total

1.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

Review 2.  Insulin-like growth factor: current concepts and new developments in cancer therapy.

Authors:  Erin R King; Kwong-Kwok Wong
Journal:  Recent Pat Anticancer Drug Discov       Date:  2012-01       Impact factor: 4.169

3.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

4.  A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

Authors:  Bradley J Monk; John A Blessing; Daron G Street; Carolyn Y Muller; James J Burke; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2011-10-13       Impact factor: 5.482

5.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

6.  Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Authors:  Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

Review 7.  Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.

Authors:  Frédéric Amant; An Coosemans; Vincent Renard; Els Everaert; Ignace Vergote
Journal:  Int J Gynecol Cancer       Date:  2009-02       Impact factor: 3.437

8.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

Authors:  Katherine Y Look; Alan Sandler; John A Blessing; Joseph A Lucci; Peter G Rose
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

9.  Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study.

Authors:  J R van Nagell; M B Hanson; E S Donaldson; H H Gallion
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

10.  Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.

Authors:  B A Goff; L W Rice; D Fleischhacker; H G Muntz; S S Falkenberry; N Nikrui; A F Fuller
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

View more
  1 in total

1.  Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma.

Authors:  Laura P Brandt; Joachim Albers; Tomas Hejhal; Antonella Catalano; Peter J Wild; Ian J Frew
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.